Quick Answer
Universe Pharmaceuticals INC reported Total Revenue of $17.86 billion for fiscal year 2025.
Universe Pharmaceuticals INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $17.86B -22.4% |
$23.02B -28.7% |
$32.31B +80383.8% |
$40.14M -16.3% |
$47.98M +56.3% |
$30.70M -7.6% |
| Net Income | -$3.67B +57.9% |
-$8.73B -32.6% |
-$6.58B -83102.6% |
-$7.91M -169.9% |
$11.32M +49.8% |
$7.56M |
| Diluted EPS | -$8.06 +98.7% |
-$626.96 +42.4% |
-$1089.21 +16.8% |
-$1309.11 -36667.3% |
$3.58 +661.7% |
$0.47 |
| Total Assets | $69.30B +2.0% |
$67.95B +162762.2% |
$41.72M -29.9% |
$59.54M -15.1% |
$70.14M +143.5% |
$28.80M |
| Cash and Equivalents | — | — | — | — | $8.08M -19.7% |
$10.06M +216.6% |
| Stockholders Equity | $56.13B +23.4% |
$45.50B +62.7% |
$27.97B -20.8% |
$35.33B +75083.6% |
$46.99M +125.9% |
$20.80M +68.0% |
| R&D Expense | $671.76M -77.8% |
$3.03B -37.6% |
$4.86B +63457.2% |
$7.64M +39.9% |
$5.47M +837.3% |
$583.1K -5.7% |
| Operating Income | -$2.92B +63.6% |
-$8.02B -102.2% |
-$3.97B -56401.6% |
-$7.02M -151.7% |
$13.59M +32.6% |
$10.25M +5.1% |
| Gross Profit | $6.30B +3.8% |
$6.07B -41.1% |
$10.32B +47019.7% |
$21.89M -13.6% |
$25.33M +79.7% |
$14.09M +5.1% |
| Shares Outstanding | 563,338 +1213.8% |
42,880 +607.4% |
6,062 -99.8% |
3.62M -83.3% |
21.75M +35.9% |
16.00M |
- Universe Pharmaceuticals INC reported Total Revenue of $17.86 billion for fiscal year 2025.
- Universe Pharmaceuticals INC showed a decrease of -22.4% in Total Revenue compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Net Income of -$3.67 billion for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +57.9% in Net Income compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Diluted EPS of $8.06 per share (loss) for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +98.7% in Diluted EPS compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Total Assets of $69.30 billion for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +2.0% in Total Assets compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Cash and Equivalents of $8.08 million for fiscal year 2021.
- Universe Pharmaceuticals INC showed a decrease of -19.7% in Cash and Equivalents compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Stockholders Equity of $56.13 billion for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +23.4% in Stockholders Equity compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported R&D Expense of $671.76 million for fiscal year 2025.
- Universe Pharmaceuticals INC showed a decrease of -77.8% in R&D Expense compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Operating Income of -$2.92 billion for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +63.6% in Operating Income compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Gross Profit of $6.30 billion for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +3.8% in Gross Profit compared to the prior fiscal year.
- Universe Pharmaceuticals INC reported Shares Outstanding of 563.3 thousand shares for fiscal year 2025.
- Universe Pharmaceuticals INC showed an increase of +1213.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: